Latest Expert Opinions

Signal
Opinion
Expert
BUY WEAKNESS
BUY WEAKNESS
May 17, 2004
Likes their technology. Good management stability. Have key brand name clients that are starting to sign up. Could drop another 20/30%.
Show full opinionHide full opinion
Bioscript (BYT-T)
May 17, 2004
Likes their technology. Good management stability. Have key brand name clients that are starting to sign up. Could drop another 20/30%.
SELL
SELL
May 17, 2004
Can't stand how they have executed. Rumors of a financial restructuring are hitting the stock. Just raised $40 million.
Show full opinionHide full opinion
SR Telecom (SRX-T)
May 17, 2004
Can't stand how they have executed. Rumors of a financial restructuring are hitting the stock. Just raised $40 million.
BUY
BUY
May 17, 2004
Have sold a lot of businesses and the remaining one is pretty well tied to the economy. New management has turned it around nicely.
Show full opinionHide full opinion
Have sold a lot of businesses and the remaining one is pretty well tied to the economy. New management has turned it around nicely.
BUY
BUY
May 17, 2004
Just reported and their earnings were fine but the stock didn't do much. Great balance sheet with $2 a share in cash. Just a matter of time. Good risk return.
Show full opinionHide full opinion
Just reported and their earnings were fine but the stock didn't do much. Great balance sheet with $2 a share in cash. Just a matter of time. Good risk return.
BUY
BUY
May 17, 2004
Just signed a big 10 year contract in the Middle East. Seems to be paid a dividend each quarter.
Show full opinionHide full opinion
Just signed a big 10 year contract in the Middle East. Seems to be paid a dividend each quarter.
WAIT
WAIT
May 17, 2004
Likes some of their businesses, but not others because of competition. Would look at it at a lower price.
Show full opinionHide full opinion
Likes some of their businesses, but not others because of competition. Would look at it at a lower price.
HOLD
HOLD
May 17, 2004
Johnson and Johnson have come back as a competitive threat on their stents. Long-term will be good. Multiple may be a bit rich.
Show full opinionHide full opinion
Johnson and Johnson have come back as a competitive threat on their stents. Long-term will be good. Multiple may be a bit rich.